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To the Editor,
We read with great interest the article ‘‘Application of
diffusion-weighted magnetic resonance imaging to predict
the intracranial metastatic tumor response to gamma knife
radiosurgery’’ by Lee, Wintermark, Xu, Yen, Schlesinger
and Sheehan (J Neurooncol. 2014 Jun; 118(2):351–61).
Our group has recently undertaken investigation of
DWI/ADC features in resected brain metastases in order to
relate these to tissue characteristics and clinical outcomes.
The authors present a series of mixed tumor types and add
to the increasing evidence that DWI/ADC is a promising
marker in these and other brain tumours, due to its ease of
acquisition (both in terms of time on the scanner and cost)
and robust, logical relation to tissue features such as
cellularity.
Brain metastasis studies of all varieties are made dif-
ficult by the variable behaviour of tumors depending on
their primary cancer of origin. The authors suggest
‘‘further studies are required to assess whether DWI/ADC
changes are influenced by type of primary cancer.’’ In fact
we have determined as previous researchers have noted
(1) that ADC values of brain metastases do indeed differ
depending on the primary cancer although this may not be
sufficient to distinguish the primary pre-operatively as it
is such a crude measure. Rather, values may be lower for
more cellular, undifferentiated tumors such as small cell
lung cancer compared to better differentiated types such
as breast and lung adenocarcinoma (2). We found, how-
ever, that this did not limit the applicability of ADC as a
predictor of outcomes after surgery and the predictive
relationship was maintained even when analysing tumors
from a single primary cancer type, in this case lung
adenocarcinoma.
Second, the authors note that the ‘‘the placement of the
ROI  relies upon the skill as well as the subjectivity of the
authors’’. We have also found this practical issue to be a
problem and it may well deter clinical radiologists from
using such techniques routinely. In support of wider clin-
ical use, we assessed a number of ADC/DWI metrics for a
small series of brain metastases and confirmed good inter-
and intra-observer agreement when various measures were
taken by a senior neuroradiologist and a neuroscience
researcher as well as good agreement using different clin-
ically available workstations for post-processing(3). Simi-
lar studies have been performed in other organs and other
tumors with differing results and more work is clearly
needed.
We look forward to further larger studies validating
DWI/ADC imaging markers as predictors of outcomes for
brain metastases, be it the response to SRS or the survival
after surgery. The value of a simple measure, which can be
obtained from a widely available sequence, should not be
underestimated.
Many thanks for this important study,
Yours sincerely,
Dr R Zakaria MA, Clinical Research Fellow in Neuro-
surgery, The Walton Centre NHS Foundation Trust &
Institute of Integrative Biology, University of Liverpool,
UK.
Mr MD Jenkinson PhD, The Walton Centre NHS
Foundation Trust & University of Liverpool, UK.
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